Secretome Therapeutics

Secretome Therapeutics has recruited experienced clinical, operational, medical affairs and finance executives as the private biotechnology company prepares to move STM-01 deeper into development for Duchenne muscular dystrophy-associated cardiomyopathy. The appointments indicate that Secretome is building the organisation required for late-stage trials and potential commercialisation, although the ultimate value of that infrastructure will depend on whether STM-01 produces convincing clinical evidence.